Osteoprotegerin is associated with hip fracture incidence: the Tromso Study | Zendy

Lone Jørgensen | Zendy; JohnBjarne Hansen | Zendy; Luai A. Ahmed | Zendy; Åshild Bjørnerem | Zendy; Nina Emaus | Zendy; Ragnar M. Joakimsen | Zendy; E. B. Mathiesen | Zendy; Jan Störmer | Zendy; Anders Vik | Zendy; Bjarne K. Jacobsen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Osteoprotegerin is associated with hip fracture incidence: the Tromso Study

Author(s) -

Lone Jørgensen,

JohnBjarne Hansen,

Luai A. Ahmed,

Åshild Bjørnerem,

Nina Emaus,

Ragnar M. Joakimsen,

E. B. Mathiesen,

Jan Störmer,

Anders Vik,

Bjarne K. Jacobsen

Publication year - 2012

Publication title -

international journal of epidemiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.406

H-Index - 208

eISSN - 1464-3685

pISSN - 0300-5771

DOI - 10.1093/ije/dys063

Subject(s) - medicine , quartile , osteoprotegerin , hip fracture , incidence (geometry) , confounding , confidence interval , population , bone resorption , osteoporosis , endocrinology , environmental health , physics , receptor , activator (genetics) , optics

Osteoprotegerin (OPG) is a cytokine essential for the regulation of bone resorption, but large longitudinal studies on its relationship to fracture risk in humans are lacking. In this population-based study of 2740 men and 2857 post-menopausal women, it was examined whether serum OPG was associated with hip fracture incidence. The participants were followed for 15 years.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research